News Archives - Page 10 of 10 - Buhlmann Diagnostics Corp

Category: News

BUHLMANN announces new Microsite for Kinase Inhibition Assay

BÜHLMANN’s Kinase Inhibition Assay Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3K γ, BTK and SYK Activity Biomarker assays are developed specifically for pharmacokinetic and pharmacodyamic (PK/PD) models during drug discovery and are often used to test efficacy and toxicity. Inhibitors of PI3K, BTK and SYK pathways are a large focus for pharmaceutical
Continue Reading

BÜHLMANN CAST® Drug Allergens: New Products

We are pleased to announce 2 new BÜHLMANN CAST® Drug Allergens: Tramadol and Metoprolol In order to meet the needs of your Cellular Allergy testing, we are offering an extended allergen portfolio by enriching this product line with new Analgesic and Beta Blocker allergens. Tramadol and Metroprolol are for Research Use Only.  Not for use in diagnostic procedures.
Continue Reading

Testing Potency and Efficacy of Inhibitors of P13K, SYK, BTK Activity

The Flow CAST® is intended for the determination of basophil activation in whole blood samples by flow cytometry. Our unique marker combination – CCR3 and CD63 – combines the simple gating properties for basophil detection by CCR3 with the solid application of the proven activation marker CD63 in one. Thanks to its easy protocol and smart
Continue Reading

New Health Canada License for BÜHLMANN fCAL® turbo

BÜHLMANN fCAL® turbo Speed, Quality and Flexibility in Calprotectin Quantification BUHLMANN Diagnostics Corp (BDC), BÜHLMANN Laboratories AG’s North American affiliate is proud to announce that its innovative product, BÜHLMANN fCAL® turbo, has received a Medical Device License from Health Canada and is now commercially available in Canada.  The device was approved as a Class 2
Continue Reading

Calprotectin Video from Canadian Digestive Health Foundation (CDHF)

The Canadian Digestive Health Foundation (CDHF) has recently produced a very interesting video about the use of calprotectin to confirm and predict flares in inflammatory bowel disease patients and how it can be used to manage IBD.

Continue Reading

Connect with BUHLMANN Diagnostics Corp at CDDW 2016

When: February 26 - 29, 2016 Where: Montreal, Quebec, Canada - Fairmont Queen Elizabeth Hotel' Booth: #1050 More Information Canadian Digestive Diseases Week
Continue Reading

Market Launch Of CALEX Device

  BÜHLMANN announces the launch and introduction of the brand new stool extraction device CALEX® Cap. The features of the CALEX® extraction tool are unique in the market: Ease of use for laboratory personnel and subjects Application as primary tube for all ELISA robots on the market An optimized sample dilution for maximum efficiency in

Continue Reading